West Pharmaceutical Services
- Market cap
- 25.79B
- P/E (TTM)i
- 46.92
- P/Bi
- 8.63
- EPSi
- 6.79
- Div yieldi
- 0.24%
- 52W posi
- 88%
Anonymous reader poll. Unscientific, not investment advice.
Shares of West Pharmaceutical Services closed at 366.48, down 1.65%. That leaves the company valued at approximately 25.79B, the #752 most valuable US-listed company we track. Valuation-wise, the P/E sits at 47.47, 12% above the five-year average of 42.50. It pays a dividend yielding 0.24% on a trailing basis. The 10 analysts covering the stock are, on balance, at Buy, targeting an average of 412.11 (+12%). Against a 52-week band of 223.52-385.75, the shares are currently 88% of the way up.
✦ StockVane Quant Insights how this is computed
- Twelve-month momentum in the top 24% of the universe, above its 200-day average.
- Signal has read BUY for 2 months.
- Its last 4 Buy calls have averaged close to flat (-1%) three months out - no strong edge on this name specifically.
- Recent price momentum is +20.6% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Analyst tilt is Buy.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 977 U.S. stocks StockVane covers.
Valuation D
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 48.2x | Better than 13% |
| Forward P/E | 41.1x | Better than 11% |
| Price / Sales | 7.8x | Better than 15% |
| P/E vs own 5-yr range | 71st pctl | Better than 37% |
Growth C-
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 2.1% | Better than 29% |
| Net income CAGR (3Y) | -5.5% | Better than 29% |
| Free cash flow CAGR (3Y) | 2.2% | Better than 37% |
Profitability B
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 35.9% | Better than 38% |
| Operating margin | 20.7% | Better than 67% |
| Net margin | 16.1% | Better than 65% |
| Return on equity | 16.9% | Better than 60% |
| Return on invested capital | 14.8% | Better than 73% |
Momentum A
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 5.9% | Better than 68% |
| 6-month return | 45.5% | Better than 88% |
| 12-month return (ex latest month) | 27.2% | Better than 63% |
| Distance below 52-week high | 2.3% | Better than 95% |
Financial Health A
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 3.0x | Better than 82% |
| Debt to assets | 7.5% | Better than 81% |
| Interest coverage | 1,202.8x | Better than 99% |
| Free cash flow / net income | 95.0% | Better than 36% |
Analyst View B-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 80% |
| Upside to average target | 9.4% | Better than 16% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector, so capital-light software tends to grade lower there than utilities. Recomputed every 6 hours from our market data. Not investment advice, and not tailored to your financial situation, goals, or risk tolerance.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 372.64
- Open
- 371.66
- Day range
- 365.35 - 374.79
- Avg price
- 368.70
- Volume
- 438.04K
- Turnover
- 161.51M
- Turnover ratei
- 0.63%
- Volume ratioi
- 0.81
- Amplitudei
- 2.54%
- 52-week rangei
- 223.52 - 385.75
Valuation
- P/Ei
- 53.97
- P/E (TTM)i
- 46.92
- P/Bi
- 8.63
- EPSi
- 6.79
- Book value / shi
- 42.49
- Net profit
- 477.85M
- Net assets
- 2.99B
Share structure
- Market cap
- 25.79B
- Float capi
- 25.60B
- Shares out
- 70.38M
- Float sharesi
- 69.85M
Dividend & listing
- Div yield (TTM)i
- 0.24%
- Dividend (TTM)
- 0.87
- Listing date
- 1970-01-01
5.0% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-23.38M net over the window
Short interest
- Shares short
- 2.38M
- % of floati
- 3.38%
- Days to coveri
- 4.51
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of West Pharmaceutical Services (WST)?
West Pharmaceutical Services last traded at 366.48. The quote on this page refreshes every few seconds while US markets are open.
What is West Pharmaceutical Services's market cap?
About 25.79B.
What is the P/E ratio of West Pharmaceutical Services?
The trailing twelve-month P/E is 46.92, above its own 5-year average of 42.50 — toward the top of its historical range (71.35% percentile). See the Valuation tab for the full history.
Does West Pharmaceutical Services pay a dividend?
Yes. The trailing dividend yield is 0.24%. The 2025 payout was up 4.9% from 2024. See the Dividends tab for the full payment history.
Is West Pharmaceutical Services a buy according to analysts?
The consensus of 10 analysts is a Buy rating, with an average 12-month price target of 412.11, which implies 12.5% upside from the current price. This is not investment advice.
What is West Pharmaceutical Services's StockVane Quant Rating?
The StockVane Momentum strategy currently rates West Pharmaceutical Services a B (Buy). Twelve-month momentum in the top 24% of the universe, above its 200-day average. Not investment advice.
Quote time 2026-10-08 07:35:06 · For reference only, not investment advice and not tailored to your situation.